Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring

被引:4
|
作者
Zhou, Yangkun [1 ]
Yue, Yang [1 ]
Fan, Siyu [1 ]
Jia, Qiaojun [1 ]
Ding, Xianfeng [1 ]
机构
[1] Zhejiang Sci Tech Univ, Sch Life Sci & Med, Hangzhou 310018, Peoples R China
关键词
Triple-negative breast cancer (TNBC); Long non-coding RNA (lncRNA); Biomarker; Therapeutic target; LONG NONCODING RNA; PROMOTES PROLIFERATION; CELL-PROLIFERATION; INVASION; METASTASIS; APOPTOSIS; PROTEIN; IDENTIFICATION; SUPPRESSES; RESISTANCE;
D O I
10.1007/s12033-021-00368-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have shown that long non-coding RNAs (lncRNAs) are involved in several gene expression regulation processes, including epigenetic regulation, transcriptional regulation, post-transcriptional regulation, and translation regulation. It also plays a crucial role in the regulation of several characteristics of cancer biology, and the dysregulation of lncRNA expression in cancer may be part of the cause of cancer progression. Meanwhile, more and more studies are trying to determine the association between lncRNA expression and TNBC, as well as the functional role and molecular mechanism of the abnormally expressed lncRNA. Therefore, this review lists some abnormal lncRNAs in TNBC, further analyzes their molecular mechanisms and biological roles in the development of TNBC, and summarizes the potential of lncRNAs as biomarkers and therapeutic targets of TNBC, so as to provide ideas for clinical diagnosis, targeted therapy, and prognosis monitoring of TNBC.
引用
收藏
页码:1093 / 1102
页数:10
相关论文
共 50 条
  • [41] Clinical characteristics of triple-negative breast cancer
    Hur, M. H.
    Im, R. J.
    Lee, S.
    Yoon, C. S.
    Ko, S. S.
    Lee, H.
    Kim, J. Y.
    Lee, J. H.
    Kang, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Novel Selenoesters as a Potential Tool in Triple-Negative Breast Cancer Treatment
    Radomska, Dominika
    Czarnomysy, Robert
    Szymanowska, Anna
    Radomski, Dominik
    Dominguez-Alvarez, Enrique
    Bielawska, Anna
    Bielawski, Krzysztof
    CANCERS, 2022, 14 (17)
  • [43] CDKs inhibitor: potential monotherapy for treatment of triple-negative breast cancer
    Rajput, Sandeep
    Guo, Zhanfang
    Ma, Cynthia
    CANCER RESEARCH, 2015, 75
  • [44] Potential role of targeted therapies in the treatment of triple-negative breast cancer
    Jia, Lee Yueh
    Shanmugam, Muthu K.
    Sethi, Gautam
    Bishayee, Anupam
    ANTI-CANCER DRUGS, 2016, 27 (03) : 147 - 155
  • [46] Postneoadjuvant treatment for triple-negative breast cancer
    Trapani, Dario
    Ferraro, Emanuela
    Giugliano, Federica
    Bielo, Luca Boscolo
    Curigliano, Giuseppe
    Burstein, Harold J.
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (06) : 623 - 634
  • [47] Treatment Horizons for Triple-negative Breast Cancer
    Yeo, W.
    HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (02): : 111 - 118
  • [48] Triple-negative breast cancer: is there a treatment on the horizon?
    Yao, Hui
    He, Guangchun
    Yan, Shichao
    Chen, Chao
    Song, Liujiang
    Rosol, Thomas J.
    Deng, Xiyun
    ONCOTARGET, 2017, 8 (01) : 1913 - 1924
  • [49] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5
  • [50] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    CANCER JOURNAL, 2021, 27 (01): : 50 - 58